VEYVONDI Powder and solvent for solution for injection Ref.[27668] Active ingredients: Von Willebrand factor

Source: Medicines & Healthcare Products Regulatory Agency (GB)  Revision Year: 2020  Publisher: Baxalta Innovations GmbH, IndustriestraรŸe 67, 1221 Vienna, Austria

Product name and form

VEYVONDI 650 IU powder and solvent for solution for injection.

VEYVONDI 1300 IU powder and solvent for solution for injection.

Pharmaceutical Form

Powder and solvent for solution for injection.

The powder is a white to off-white lyophilized powder.

The solvent is a clear and colourless solution.

Qualitative and quantitative composition

VEYVONDI 650 IU powder and solvent for solution for injection:

Each vial of powder contains nominally 650 International Units (IU) vonicog alfa.

After reconstitution with the 5 mL solvent provided, VEYVONDI contains approximately 130 IU/mL vonicog alfa.

VEYVONDI 1300 IU powder and solvent for solution for injection:

Each vial of powder contains nominally 1300 International Units (IU) vonicog alfa.

After reconstitution with the 10 mL solvent provided, VEYVONDI contains approximately 130 IU/mL vonicog alfa

The specific activity of VEYVONDI is approximately 110 IU VWF:RCo/mg protein.

The potency of VWF (IU) is measured using the European Pharmacopeia ristocetin cofactor activity assay (VWF: RCo). The ristocetin cofactor activity of recombinant human von Willebrand factor was determined against the International Standard for von Willebrand factor concentrate (WHO).

Vonicog alfa is a purified recombinant human von Willebrand factor (rVWF). It is manufactured by recombinant DNA (rDNA) technology in the Chinese Hamster Ovary (CHO) cell line without the addition of any exogenous human-or animal-derived protein in the cell culture process, purification or final formulation.

The product contains only trace amounts of human recombinant coagulation factor VIII (โ‰ค0.01 IU FVIII / IU VWF: RCo) as determined using the European Pharmacopoeia chromogenic assay for factor VIII (FVIII).

Excipient(s) with known effect:

Each 650 IU powder vial contains 5.2 mg sodium.

Each 1300 IU powder vial contains 10.4 mg sodium.

For the full list of excipients, see section 6.1.

Active Ingredient Description
Von Willebrand factor

Administration of von Willebrand factor allows correction of the haemostatic abnormalities exhibited by patients who suffer from von Willebrand factor deficiency.

List of Excipients

Powder:

Sodium citrate
Glycine
Trehalose dihydrate
Mannitol
Polysorbate 80

Solvent:

Water for injections

Pack sizes and marketing

VEYVONDI 650 IU powder and solvent for solution for injection

Each pack contains:

  • powder in a vial (type I glass), with a butyl rubber stopper
  • 5 mL of solvent in a vial (type I glass), with a rubber stopper (chlorobutyl)
  • one reconstitution device (Mix2Vial)

VEYVONDI 1300 IU powder and solvent for solution for injection

Each pack contains:

  • powder in a vial (type I glass), with a butyl rubber stopper
  • 10 mL of solvent in a vial (type I glass), with a rubber stopper (bromobutyl)
  • one reconstitution device (Mix2Vial)

Marketing authorization holder

Baxalta Innovations GmbH, IndustriestraรŸe 67, 1221 Vienna, Austria

Marketing authorization dates and numbers

EU/1/18/1298/001
EU/1/18/1298/002

Date of first authorisation: 31 August 2018

Drugs

Drug Countries
VEYVONDI Austria, Estonia, Finland, France, Croatia, Ireland, Italy, Lithuania, Netherlands, Poland, Romania, United Kingdom

ยฉ All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.